Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

SymBio Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Myelodysplastic Syndrome

Treatments: Drug: SyB C-1101

Study type: Interventional

Funder types: Industry

Identifiers

NCT03495167

2017001

Details and patient eligibility

About

To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.

Enrollment: 10 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients who meet all of the following criteria are eligible for enrollment in the study:

1. Histologically or cytologically diagnosed as myelodysplastic syndrome (MDS) according to WHO criteria or FAB classification. For patients with RAEB in transformation (RAEB-t), peripheral WBC is ≦25,000 /mm3 and the disease is stable for at least 4 weeks.

2. Classified as Intermediate-1, Intermediate-2 or High-risk, according to IPSS classification.

3. Patients with a history of previous treatment of the target disease (e.g., immunosuppressive therapy, protein anabolic steroids, and chemotherapy including azacitidine and lenalidomide) and meet one of the followings:

   • Patients who failed to achieve complete remission, partial remission, or hematologic improvement*
   • Patients experienced with recurrence/relapse after achieving complete remission, partial remission, or hematologic improvement*
   • Patients who were intolerable to the previous therapy *: The most recent assessment of the therapeutic effect based on "Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia" (IWG2006 criteria)

4. Off all other treatment (including erythropoiesis stimulating agents) for MDS, for at least 4 weeks prior to enrollment and no carry-over (of antitumor effect) from previous treatment is expected as judged by Investigator. Transfusion is allowed, as clinically indicated.

5. Patients with expected survival of ≥3 months.

6. Patients aged 20 years or older (at the time of informed consent).

7. ECOG Performance Status (PS) of 0, 1 or 2

8. Patients with adequate major organ functions (including the heart, lungs, liver, and kidneys).

   • AST (GOT): ≤2.5 -fold the upper limit of normal range at each institution
   • ALT (GPT) : ≤2.5 -fold the upper limit of normal range at each institution
   • Total bilirubin: <2.0 mg/dL (except patients with Gilbert's disease or hemolysis)
   • Serum creatinine: <2.0 mg/dL
   • ECG: Absence of abnormal findings that require treatment
   • Echocardiography: Absence of abnormal findings that require treatment

9. The patient must sign an informed consent form indicating that s/he understands the purpose of and procedure required for the study and is willing to participate in the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

SyB C-1101

Experimental group

Treatment:

Drug: SyB C-1101